We believe that this study is novel in suggesting that the measurement of IF-ANA before TNFi in RA may help predict secondary failure and adverse events through estimation of ADrA appearance and in directly showing that the interaction of immunogenicity with autoimmunity could be brought during anti-TNF therapy. The gene discussed is TNF; the disease is rheumatoid arthritis.